Clinical Trial Search

Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0 to Inf]) for GSK3640254-Part 1 — 36.94; 36.88 Hours*microgram per milliliter

Primary: Safety as Measured by the Number of Participants Experiencing Adverse Events — 16 Participants

Primary: Incidence of Relapse of Acute Myeloid Leukemia Based on the International Working Group Response Criteria — 2; 2; 2 participants

Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) — 11; 2; 6; 8 Participants

Primary: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) — 40.0; 0; 0; 0 percentage of participants

Primary: Area Under the Plasma Concentration of BCD-089-time Curve From Zero (0) Hours to 1680 Hours After the Single Subcutaneous Injection of BCD-089 — 0; 15567.9; 44568.6…

Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Based on Severity to SHP681 in Single Ascending Dose (SAD) — 3; 3; 2; 4…

Primary: Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours (AUC0-24) of Talazoparib on Day 22 — 111.8; 159.0; 123.6; NA nanogram*hour per milliliter

Primary: Cmax: Maximum Observed Serum Concentration — 86100; 81100; 87500 (ng/mL)/(mg/mL)

Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants

Primary: Maximum Plasma Concentration (Cmax) of OPC-34712 — 47.4; 44.9; 46.1 ng/mL

Primary: Number of Participants With of Adverse Events (AEs) — 3; 1; 1; 1 Count of Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants

Primary: Number of Participants With 0 to 4 Investigator's Global Assessment Score at Week 6 — 0; 0; 3; 3 Participants